Dr. Reddy’s Laboratories Limited (NYSE:RDY) Stock Position Raised by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. lifted its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 453.8% in the 4th quarter, HoldingsChannel.com reports. The fund owned 11,438,908 shares of the company’s stock after acquiring an additional 9,373,412 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Dr. Reddy’s Laboratories were worth $180,620,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Farther Finance Advisors LLC boosted its stake in shares of Dr. Reddy’s Laboratories by 43.2% during the 3rd quarter. Farther Finance Advisors LLC now owns 454 shares of the company’s stock worth $36,000 after acquiring an additional 137 shares in the last quarter. Venturi Wealth Management LLC acquired a new stake in shares of Dr. Reddy’s Laboratories in the third quarter worth $60,000. Van ECK Associates Corp boosted its position in shares of Dr. Reddy’s Laboratories by 64.3% in the third quarter. Van ECK Associates Corp now owns 823 shares of the company’s stock worth $64,000 after buying an additional 322 shares during the period. GAMMA Investing LLC boosted its position in shares of Dr. Reddy’s Laboratories by 83.2% in the third quarter. GAMMA Investing LLC now owns 1,447 shares of the company’s stock worth $115,000 after buying an additional 657 shares during the period. Finally, Glenmede Trust Co. NA acquired a new stake in shares of Dr. Reddy’s Laboratories in the third quarter worth $207,000. 3.85% of the stock is owned by institutional investors.

Analysts Set New Price Targets

RDY has been the subject of several recent analyst reports. StockNews.com cut Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th. Nomura cut Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th. Finally, Barclays decreased their target price on Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th.

Dr. Reddy’s Laboratories Stock Performance

Shares of RDY stock opened at $13.52 on Wednesday. Dr. Reddy’s Laboratories Limited has a fifty-two week low of $13.36 and a fifty-two week high of $16.89. The stock’s 50-day moving average is $14.84 and its two-hundred day moving average is $15.49. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.36. The firm has a market cap of $11.29 billion, a P/E ratio of 21.60 and a beta of 0.51.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 18.53% and a net margin of 17.81%. Analysts predict that Dr. Reddy’s Laboratories Limited will post 0.81 earnings per share for the current fiscal year.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.